BioRestorative Therapies (NASDAQ:BRTX) Announces Earnings Results

BioRestorative Therapies (NASDAQ:BRTX) issued its quarterly earnings results on Tuesday. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.06, Yahoo Finance reports. BioRestorative Therapies had a negative return on equity of 96.09% and a negative net margin of 7,303.33%. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.03 million. During the same period in the previous year, the company earned ($0.77) earnings per share.

BioRestorative Therapies Trading Up 1.4 %

BRTX stock traded up $0.02 during trading on Thursday, hitting $1.42. The company had a trading volume of 17,790 shares, compared to its average volume of 1,070,982. The company has a fifty day moving average price of $1.69 and a two-hundred day moving average price of $1.50. BioRestorative Therapies has a fifty-two week low of $1.03 and a fifty-two week high of $3.67. The company has a market cap of $9.61 million, a P/E ratio of -0.61 and a beta of 63.47.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm boosted their price target on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.